Target Name: OR2H2
NCBI ID: G7932
Review Report on OR2H2 Target / Biomarker Content of Review Report on OR2H2 Target / Biomarker
OR2H2
Other Name(s): OLFR2 | MGC126732 | olfactory receptor 2H3 | olfactory receptor OR6-36 | Olfactory receptor-like protein FAT11 | Olfactory receptor, family 2, subfamily H, member 3 | Olfactory receptor 2H2 | OTTHUMP00000029058 | FAT11 | olfactory receptor, family 2, subfamily H, member 3 | Olfactory receptor 2 | Olfactory receptor 2H3 | dJ271M21.2 | olfactory receptor-like protein FAT11 | DJ271M21.2 | hs6M1-12 | Hs6M1-12 | Olfactory receptor OR6-36 | Olfactory receptor-like protein | MGC138381 | OR2H3 | OR2H2_HUMAN | OLFR42B | olfactory receptor family 2 subfamily H member 2 | Olfactory receptor family 2 subfamily H member 2

OR2H2: A Potential Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer death in women, affecting an estimated 21,120 women in the United States alone in 2020. Despite advances in treatment, the survival rate for ovarian cancer remains poor, with a five-year survival rate of only 40%. The need for new treatments and better understanding of the underlying biology of ovarian cancer is greater than ever.

One potential solution to this problem is OR2H2, a protein that is expressed in high levels in ovarian cancer cells. OR2H2 has been shown to promote the growth and survival of ovarian cancer cells in cell culture and animal models. It is also associated with poor prognosis in ovarian cancer patients.

OR2H2 is a transmembrane protein that is expressed in various tissues and cells, including the uterus, breast tissue, and blood vessels. It is a potential drug target because of its involvement in the development and progression of ovarian cancer. Studies have shown that high levels of OR2H2 are associated with poor prognosis in ovarian cancer patients, and that inhibiting OR2H2 may be an effective way to treat ovarian cancer.

One way to target OR2H2 is through inhibition of its downstream signaling pathways. One such pathway is the PI3K/Akt signaling pathway, which is involved in cell survival and proliferation. Studies have shown that OR2H2 is a negative regulator of the PI3K/Akt pathway, and that inhibition of OR2H2 may be an effective way to inhibit the growth and survival of ovarian cancer cells.

Another potential way to target OR2H2 is through inhibition of its interaction with other proteins. OR2H2 has been shown to interact with various proteins, including the transcription factor E2F1, which is involved in the development and progression of cancer. Studies have shown that OR2H2 can promote the growth and survival of ovarian cancer cells by interacting with E2F1 and that inhibition of OR2H2 may be an effective way to treat ovarian cancer.

In addition to its potential as a drug target, OR2H2 may also be a biomarker for ovarian cancer. Studies have shown that OR2H2 is overexpressed in ovarian cancer tissue and that high levels of OR2H2 are associated with poor prognosis in ovarian cancer patients. This suggests that OR2H2 may be a useful biomarker for ovarian cancer and that its levels may be a useful target for diagnostic and therapeutic studies.

In conclusion, OR2H2 is a potential drug target and biomarker for ovarian cancer. Its involvement in the development and progression of ovarian cancer and its association with poor prognosis in ovarian cancer patients make it an attractive target for therapeutic studies. inhibition of OR2H2 may be an effective way to treat ovarian cancer and its levels may be a useful biomarker for diagnostic studies. Further research is needed to fully understand the role of OR2H2 in ovarian cancer and to develop effective treatments.

Protein Name: Olfactory Receptor Family 2 Subfamily H Member 2

Functions: Odorant receptor

The "OR2H2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR2H2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR2I1P | OR2J1 | OR2J2 | OR2J3 | OR2J4P | OR2K2 | OR2L13 | OR2L1P | OR2L2 | OR2L3 | OR2L5 | OR2L8 | OR2L9P | OR2M1P | OR2M2 | OR2M3 | OR2M4 | OR2M5 | OR2M7 | OR2Q1P | OR2S2 | OR2T1 | OR2T10 | OR2T11 | OR2T12 | OR2T2 | OR2T27 | OR2T29 | OR2T3 | OR2T33 | OR2T34 | OR2T35 | OR2T4 | OR2T5 | OR2T6 | OR2T7 | OR2T8 | OR2U1P | OR2V1 | OR2V2 | OR2W1 | OR2W1-AS1 | OR2W3 | OR2W5P | OR2W6P | OR2Y1 | OR2Z1 | OR3A1 | OR3A2 | OR3A3 | OR3A4P | OR4A14P | OR4A15 | OR4A16 | OR4A17P | OR4A21P | OR4A47 | OR4A5 | OR4B1 | OR4C11 | OR4C12 | OR4C13 | OR4C15 | OR4C16 | OR4C1P | OR4C3 | OR4C45 | OR4C46 | OR4C5 | OR4C50P | OR4C6 | OR4D1 | OR4D10 | OR4D11 | OR4D2 | OR4D5 | OR4D6 | OR4D9 | OR4E2 | OR4F13P | OR4F15 | OR4F16 | OR4F17 | OR4F21 | OR4F29 | OR4F3 | OR4F4 | OR4F5 | OR4F6 | OR4G3P | OR4K1 | OR4K13 | OR4K14 | OR4K15 | OR4K17 | OR4K2 | OR4K5 | OR4K6P | OR4K7P | OR4L1